Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print September 28, 2005, 10.1148/radiol.2372041183
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2372041183v1
237/2/520    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lutz, A. M.
Right arrow Articles by Weishaupt, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lutz, A. M.
Right arrow Articles by Weishaupt, D.
(Radiology 2005;237:520-528.)
© RSNA, 2005


Gastrointestinal Imaging

Hepatocellular Carcinoma in Cirrhosis: Enhancement Patterns at Dynamic Gadolinium- and Superparamagnetic Iron Oxide–enhanced T1-weighted MR Imaging1

Amelie M. Lutz, MD, Jürgen K. Willmann, MD, Kerstin Goepfert, RT, Borut Marincek, MD and Dominik Weishaupt, MD

1 From the Institute of Diagnostic Radiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. Received July 6, 2004; revision requested September 14; revision received December 6; accepted January 18, 2005. Address correspondence to D.W. (e-mail: dominik.weishaupt{at}dmr.usz.ch).

PURPOSE: To prospectively compare intraindividual differences in enhancement patterns between gadolinium- and superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance (MR) imaging in patients with histologically proved hepatocellular carcinoma (HCC).

MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained. Twenty-two patients (18 men, four women; mean age, 58.9 years) with 36 pathologically proved HCC lesions underwent contrast material–enhanced dynamic T1-weighted gradient-echo MR imaging twice. Gadopentetate dimeglumine was used at the first session. After a mean interval of 5 days, a second session was performed with a bolus-injectable SPIO agent, ferucarbotran. Qualitative analysis of contrast enhancement patterns with each agent during hepatic arterial, portal venous, and equilibrium phases was performed by two readers who classified lesions as isointense, hypointense, or hyperintense compared with surrounding liver parenchyma and searched for presence of hyperintense peritumoral ring enhancement. Results of signal intensity analysis during different vascular phases at both sessions were compared by using the McNemar test, and {kappa} statistic was used to evaluate agreement between signal intensity and enhancement pattern of lesions during different vascular phases.

RESULTS: On gadolinium-enhanced hepatic arterial phase images, HCC lesions (n = 36) were hyperintense in 21 (58%) cases, hypointense in 10 (28%), and isointense in five (14%). On ferucarbotran-enhanced hepatic arterial phase images, HCC lesions were isointense in 18 (50%) cases, hypointense in 11 (31%), and hyperintense in seven (19%). On gadolinium-enhanced portal venous and equilibrium phase images, respectively, HCC lesions were hypointense in 17 (47%) and 21 (58%) cases, hyperintense in 10 (28%) cases and one (3%) case, and isointense in nine (25%) and 14 (39%) cases. On ferucarbotran-enhanced portal venous and equilibrium phase images, respectively, HCC lesions were hypointense in 15 (42%) and 11 (31%) cases, hyperintense in three (8%) and three (8%) cases, and isointense in 18 (50%) and 22 (61%) cases.

CONCLUSION: For HCC, contrast enhancement pattern on T1-weighted gradient-echo MR images shows marked variability with gadolinium or SPIO contrast agents.

© RSNA, 2005




This article has been cited by other articles:


Home page
RadioGraphicsHome page
R. F. Hanna, D. A. Aguirre, N. Kased, S. C. Emery, M. R. Peterson, and C. B. Sirlin
Cirrhosis-associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features
RadioGraphics, May 1, 2008; 28(3): 747 - 769.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
R. F. Hanna, N. Kased, S. W. Kwan, A. C. Gamst, A. C. Santosa, T. Hassanein, and C. B. Sirlin
Double-Contrast MRI for Accurate Staging of Hepatocellular Carcinoma in Patients with Cirrhosis
Am. J. Roentgenol., January 1, 2008; 190(1): 47 - 57.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
C. Heilmaier, R. Sutter, A. M. Lutz, B. Seifert, D. Weishaupt, B. Marincek, and J. K. Willmann
Mapping of Hepatic Vascular Anatomy: Dynamic Contrast-enhanced Parallel MR Imaging Compared with 64 Detector Row CT
Radiology, December 1, 2007; 245(3): 872 - 880.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
R. Schafer, R. Kehlbach, J. Wiskirchen, R. Bantleon, J. Pintaske, B. R. Brehm, A. Gerber, H. Wolburg, C. D. Claussen, and H. Northoff
Transferrin Receptor Upregulation: In Vitro Labeling of Rat Mesenchymal Stem Cells with Superparamagnetic Iron Oxide
Radiology, August 1, 2007; 244(2): 514 - 523.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2005 by the Radiological Society of North America.